H.R. 3162

119th Congress

In Committee

Affordable and Safe Prescription Drug Importation Act of 2025

Sponsored byDemocrat:Rep. Schakowsky, Janice D. [D-IL-9]IL· Introduced 1 May 2025

6

Cosponsors

3

Actions

0

Amendments

1

Committees

Since introduced

Introduced
Committee
Passed Chamber
Passed Both
Enacted
Step 1 of 0
Latest action

Referred to the House Committee on Energy and Commerce.

1 May 2025·1 year ago

Summary

Introduced in House · Updated 3 April 2026

Affordable and Safe Prescription Drug Importation Act of 2025

This bill expands the categories of prescription drugs that may be imported into the United States and the countries from which such drugs may be imported.

Current law allows the Department of Health and Human Services (HHS) to authorize importation of certain eligible prescription drugs from Canada if HHS certifies that doing so would pose no additional risk to public health and safety, among other requirements. HHS long declined to make the requisite certification, citing safety concerns (e.g., contamination, counterfeiting), but ultimately made the certification in 2020 and has since approved one state plan to import drugs.

The bill removes the certification requirement and requires HHS to issue regulations that permit importation of qualifying prescription drugs from the United Kingdom, Switzerland, and member states of the European Union, in addition to Canada. After one year, if HHS determines that importation of drugs from these countries has been conducted safely, HHS may authorize importation from other countries that meet certain requirements.

The bill also expands the types of prescription drugs eligible for importation to include, for example, biologics such as insulin.

Further, the bill allows individuals to use an eligible licensed foreign pharmacy to fill a U.S.-issued prescription for a qualifying drug for personal use. Currently, an individual seeking to import a prescription drug generally must acquire a waiver from HHS.

Finally, the bill imposes criminal penalties for websites that sell counterfeit drugs or dispense drugs without a required prescription.

Timeline

3 actions

  1. Referred to the House Committee on Energy and Commerce.

    1 May 2025 · IntroReferral

  2. Introduced in House

    1 May 2025 · IntroReferral

  3. Introduced in House

    1 May 2025 · IntroReferral

Sponsorship

6 cosponsors

Cosponsors

  • Democrat6100%

Classification

Policy area

Health

Committees

1

  • Energy and Commerce Committee

    House · Standing

    • Referred To1 May 2025

Cosponsor momentum

Cumulative over time

Cosponsors grew from 5 on 1 May 2025 to 6 on 22 July 2026.

Pelosi Tracker
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.